United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - ticagrelor - tablet - 90mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

healthcare pharmaceuticals ltd. - ticagrelor - tablet - 90 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

unimed unihealth pharmaceuticals ltd. - ticagrelor - tablet - 90 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

astrazeneca, sweden - ticagrelor - film-coated tablet - 90 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

astrazeneca ab - ticagrelor - ticagrelor....90 mg.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ticagrelor 60mg - film coated tablet - 60 mg - active: ticagrelor 60mg excipient: calcium hydrogen phosphate magnesium stearate mannitol opadry yellow 00f520007 povidone purified water sodium starch glycolate - ticagrelor-teva, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke), - in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg) and - in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - ticagrelor 60mg;  ;  ;   - film coated tablet - 60 mg - active: ticagrelor 60mg       excipient: calcium hydrogen phosphate hyprolose hypromellose iron oxide black iron oxide red macrogol 400 magnesium stearate mannitol purified water   sodium starch glycolate titanium dioxide - brilinta, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) · in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). · in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antithrombotic agents - possia, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-st-elevation myocardial infarction [nstemi] or st-elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Philippines - English - FDA (Food And Drug Administration)

astrazeneca pharmaceuticals (phils.), inc. - ticagrelor - film-coated tablet - 90 mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: n/a; distributor: n/a - ticagrelor - film-coated tablet - 90 mg